Skip to content
Triangle logo TriangleGet started
← Study library

NCT03811886 · CITED IN SOURCE DOCUMENTS

Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE1, PHASE2
Status at capture
WITHDRAWN
Registry last update
2025-01-15

The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with this treatment as well as overall survival.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Subjects may be male or female and must be equal to or greater than 5 years of age but less than or equal to 30 years of age at the time of enrollment. No large studies have evaluated the use of Natalizumab in younger pediatric patients, and Natalizumab is currently only FDA approved for adult use; for this reason, children younger than 5 years of age are excluded from this study. * Subjects must have histologic verification of pOS. * Subjects must have measurable pulmonary disease or pleural disease per RECIST 1.1 documented by clinical, radiographic and histologic criteria, and have progressed, relapsed or become refractory to conventional therapy. \-- Subjects despite having peripheral diseases elsewhere outside of pulmonary disease or pleural disease, may be eligible: * if these diseases have failed upfront standard therapy AND * one or two salvage therapies * Subjects must have recovered from the acute toxic effects with ≤ Grade 1 as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 of all prior chemotherapy and immunotherapy with the exception of alopecia, anorexia, bone pain, and tumor pain prior to entering this study. * Myelosuppressive chemotherapy: Must have adequate recovery of counts from previous treatment prior to entry onto this study. * Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody. * Subjects must have a performance status corresponding to a Karnofsky ≥ 50% for participants \> 16 years of age and Lansky ≥ 60 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score. * Subjects must have normal organ and marrow function as defined below: * Adequate bone marrow function defined as: * Peripheral absolute neutrophil count (ANC) ≥ 750/mcL * Platelet count ≥ 75,000/mcL (transfusion independent) * Hemoglobin ≥ 8.0 g/dL (may receive packed red blood cell transfusions) * Adequate liver function defined as: * Total bilirubin ≤ 1.5 times the upper limit of normal for age * AST (SGOT) and ALT (SGPT) 2.5 X institutional upper limit of normal * Serum albumin \> 2 g/dL * Adequate cardiac function defined as: * Ejection fraction of ≥ 50% by echocardiogram * Subjects must have the ability to understand and the willingness to sign a written informed consent document if ≥ 18 years of age and an assent document if \< 18 years of age. If \< 7 years of age, no assent document is required. Exclusion Criteria: The presence of any of the following will exclude a subject from study enrollment. * Patients with evidence of osteosarcoma outside of the lungs or pleura. * Ongoing prior treatment toxicities \> Grade 1 according to NCI CTCAE Version 5.0 with the exception of alopecia, anorexia, bone pain and tumor pain. * Subjects receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Natalizumab. * Subjects currently on immunosuppressive therapy. * Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, liver failure, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breastfeeding women are excluded from this study because Natalizumab crosses the placenta and can increase the risk of spontaneous abortion. There is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with Natalizumab, therefore breastfeeding should be discontinued if the mother is treated with Natalizumab. * Female participants of childbearing potential are not eligible unless a negative pregnancy test result has been obtained. * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * HIV-positive subjects and HIV-positive subjects on antiretroviral therapy are ineligible because of the risk for developing a lethal infection when treated with immunosuppressive therapy. * Participants who have or have had progressive multifocal leukoencephalopathy (PML). * Participants whose pulmonary metastatic disease or pleural disease can be completely surgically resected.
healthy Volunteers
false
maximum Age
30 Years
minimum Age
5 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Traditional 3+3 design escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed a maximum dose of 300mg Phase II treatment to continue if the participant has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS as defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If the participant has progressive disease after 6 cycles, they will be removed from the study.
    intervention Names
    1. Drug: Natalizumab
    label
    Phase I: Natalizumab
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Phase I: Natalizumab
    description
    Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors. Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg. Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study.
    name
    Natalizumab
    other Names
    1. Tysabri
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
0
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Hematologic dose limiting toxicities: Grade 4 neutropenia or thrombocytopenia of \> 7 days duration; or myelosuppression that causes a delay of \> 8 weeks between treatment courses Non-hematologic dose-limiting toxicities: Any Grade 4 non-hematologic toxicity attributable to Natalizumab with the specific exclusion of: * Grade 4 nausea and vomiting responding to anti-emetics, alopecia, fatigue and drug related fever * Grade 4 fever * Any Grade 3 or greater neurologic toxicity * Any Grade 3 or greater anaphylaxis * Any Grade 2 or greater elevation in transaminases and bilirubin levels * Any Grade 4 non-hematologic toxicities (excluding alopecia, nausea and vomiting) that do not resolve to ≤ Grade 1 by 8 weeks following the most recent dose of Natalizumab
    measure
    Dosing limiting toxicity
    time Frame
    30 days after end of treatment (1 year)
secondary Outcomes
  1. description
    Clinical benefit rate as defined by the number of participants that have Complete Response (CR), Partial Response (PR) or Stable Disease (SD) after 12 cycles
    measure
    Clinical benefit rate
    time Frame
    1 year after start of treatment
  2. description
    Overall survival measured in months and summarized using Kaplan-Meier analysis. This will be calculated from the date of registration on-study to the dates of documented evidence of progression or death, up to 3 years
    measure
    Overall survival measured in months
    time Frame
    Up to 3 years
Full study description
brief Summary
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with this treatment as well as overall survival.
detailed Description
This study is a single-arm, open-label, proof of concept clinical trial in children, adolescent and young adult patients with unresectable pOS that have progressed, relapsed or are refractory to standard systemic therapy. All participants will receive the study therapy and there will be dose escalation in a traditional 3 + 3 design during the Phase I study of this trial. In the Phase II study of the trial, treatment will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS after every 3 cycles after the first 6 cycles but not beyond 24 cycles, unless it is judged to be in his/her best interest. Approximately 3-9 subjects will be enrolled in the phase I part and 10-12 in the phase II part of this trial. Participants will be followed for toxicity for 30 days after treatment has been discontinued or until one of the protocol-defined reasons This study seeks to evaluate if Natalizumab can be used safely and effectively as immunotherapy in children, adolescent and young adult patients with pOS. Natalizumab is currently Food and Drug Administration (FDA) approved for the treatment of T-cell mediated autoimmune disorders The study team will evaluate the safety and tolerability of Natalizumab as well as the clinical response associated with Natalizumab treatment and evaluate overall survival.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-2fb844bd6a81f1068f40
      requested nct id
      NCT03811886
      primary nct id
      NCT03811886
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      2d815505d7792b5c996e13d8e7d0da752539d1baac403cdf7b5dd91c49c6c2b0
      payload sha256
      5d8616c713df9fb4725ec78210712419c6ac03256b8b6acecb6b5d8a24993cbf
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-2fb844bd6a81f1068f40
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT03811886
      occurrences
      1. context exact
        eing done to evaluate the two different surgery methods for these patients and to determine which procedure is better.</li><li><strong><a href="/clinicaltrials/NCT03811886">NCT03811886</a></strong> (Natalizumab for the Treatment of Recurrent, Refractory, or Progressive Pulmonary Metastatic Osteosarcoma)<strong>:</strong> This is
        end
        279008
        exact text
        NCT03811886
        start
        278997
      2. context exact
        evaluate the two different surgery methods for these patients and to determine which procedure is better.</li><li><strong><a href="/clinicaltrials/NCT03811886">NCT03811886</a></strong> (Natalizumab for the Treatment of Recurrent, Refractory, or Progressive Pulmonary Metastatic Osteosarcoma)<strong>:</strong> This is a phase I/II
        end
        279021
        exact text
        NCT03811886
        start
        279010
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/5f689a14832ef0c241.html
      source file sha256
      2d815505d7792b5c996e13d8e7d0da752539d1baac403cdf7b5dd91c49c6c2b0
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:30.451333+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      a64aa5622fd5aa65067793f32628c1ada8e65cdd47ac5a4cd81bffa04980a99e
      source title
      Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: December 2, 2024
        datetime
        2024-12-02T12:00:00Z
        display
        December 2, 2024

    Preserved source evidence · Not medical advice